FDA To Review Piroctone Olamine For OTC Dandruff Monograph Status
This article was originally published in The Tan Sheet
Executive Summary
FDA is seeking safety and efficacy data on piroctone olamine as a single active ingredient in dandruff control products, the agency announced in a Federal Register 1notice Feb. 18
You may also be interested in...
TEA Fee For Expedited Review Option, Dedicated Staff Increase Suggested
FDA should consider making a voluntary fee option for expedited reviews of OTC monograph time and extent applications, Ciba Specialty Chemicals recommends in April 13 comments to the agency
TEA Fee For Expedited Review Option, Dedicated Staff Increase Suggested
FDA should consider making a voluntary fee option for expedited reviews of OTC monograph time and extent applications, Ciba Specialty Chemicals recommends in April 13 comments to the agency
TEA Fee For Expedited Review Option, Dedicated Staff Increase Suggested
FDA should consider making a voluntary fee option for expedited reviews of OTC monograph time and extent applications, Ciba Specialty Chemicals recommends in April 13 comments to the agency